Calamos Advisors LLC Has $43.44 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Calamos Advisors LLC reduced its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 1.3% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 304,343 shares of the company’s stock after selling 3,998 shares during the period. Calamos Advisors LLC’s holdings in Novo Nordisk A/S were worth $43,442,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the stock. AMG National Trust Bank grew its holdings in shares of Novo Nordisk A/S by 61.5% during the second quarter. AMG National Trust Bank now owns 10,275 shares of the company’s stock worth $1,467,000 after buying an additional 3,911 shares in the last quarter. Calamos Wealth Management LLC grew its stake in shares of Novo Nordisk A/S by 7.2% during the 2nd quarter. Calamos Wealth Management LLC now owns 49,867 shares of the company’s stock worth $7,118,000 after acquiring an additional 3,368 shares in the last quarter. Independence Bank of Kentucky raised its holdings in shares of Novo Nordisk A/S by 67.0% in the second quarter. Independence Bank of Kentucky now owns 3,925 shares of the company’s stock valued at $560,000 after purchasing an additional 1,575 shares during the last quarter. Sterling Investment Counsel LLC acquired a new stake in shares of Novo Nordisk A/S in the second quarter valued at approximately $329,000. Finally, Institute for Wealth Management LLC. boosted its holdings in Novo Nordisk A/S by 1.6% during the second quarter. Institute for Wealth Management LLC. now owns 12,931 shares of the company’s stock worth $1,846,000 after purchasing an additional 200 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Argus lifted their target price on Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research report on Monday, June 10th. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Monday, August 19th. BMO Capital Markets decreased their target price on shares of Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating for the company in a research note on Thursday, August 8th. The Goldman Sachs Group started coverage on shares of Novo Nordisk A/S in a research report on Thursday, May 30th. They set a “buy” rating and a $156.00 price target on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Monday, August 19th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $145.17.

Novo Nordisk A/S Stock Performance

Shares of NYSE:NVO traded up $0.09 on Friday, hitting $136.97. The company had a trading volume of 2,112,195 shares, compared to its average volume of 4,428,083. The stock has a 50 day moving average price of $136.22 and a 200 day moving average price of $131.66. The company has a current ratio of 0.70, a quick ratio of 0.50 and a debt-to-equity ratio of 0.17. The stock has a market cap of $614.66 billion, a price-to-earnings ratio of 47.23, a P/E/G ratio of 1.33 and a beta of 0.41. Novo Nordisk A/S has a 1-year low of $86.96 and a 1-year high of $148.15.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a semi-annual dividend, which will be paid on Monday, August 26th. Stockholders of record on Friday, August 16th will be paid a dividend of $0.5126 per share. The ex-dividend date of this dividend is Friday, August 16th. This represents a dividend yield of 0.7%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 24.83%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.